Thomson Reuters Names Drugs to Watch in 2014 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Thomson Reuters Names Drugs to Watch in 2014



Thomson Reuters released its annual forecast of the leading drugs to watch in 2014, including three potential treatments anticipated to bring in more than $1 billion in sales through 2019. The analysis identified three drugs that are predicted to significantly impact the marketplace in the upcoming year.

The first drug, Sovaldi by Gilead, is an oral NS5B ploymersase inhibitor for treating hepatitis C, which is expected to reach $2.4 billion in sales in 2014, and an estimated $9.1 billion by 2019. The second is Anoro Ellipta by GSK, which contains two bronchodilators for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, with predicted sales of $3 billion through 2019. The third is Idelalisib by Gilead, an oral P13K p110-delta subunit inhibitor for indolent non-Hodgkin’s lymphoma in the US and chronic lymphocytic leukemia (CLL) in the UK. This treatment demonstrated effectiveness in a phase III CLL trial, however, idelalisib faces competition in the CLL marketplace.

The forecast cited other notable drugs including Eli Lilly’s long-acting GLP-1 analog dulaglutide for diabetes and its anti-VEGFR2 mAb Cyramza for gastric cancer, as well as MannKind’s inhaled insulin product Afrezza. This will be the third filing for Afrezza since 2009, after FDA twice requested further information.

The Thomson Reuters Market Insight report also includes an update on the 2013 Drugs to Watch, including Vascepa (Amarin), Pomalyst (Celgene), Kadcyla (Roche), and Relovair (GlaxoSmithKline, Thervance).

Source: Thomson Reuters

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here